(NASDAQ: BEAM) Beam Therapeutics's forecast annual revenue growth rate of 29.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.59%.
Beam Therapeutics's revenue in 2026 is $55,701,000.On average, 20 Wall Street analysts forecast BEAM's revenue for 2026 to be $4,749,230,329, with the lowest BEAM revenue forecast at $2,983,363,354, and the highest BEAM revenue forecast at $11,720,356,032. On average, 17 Wall Street analysts forecast BEAM's revenue for 2027 to be $6,019,189,253, with the lowest BEAM revenue forecast at $2,983,363,354, and the highest BEAM revenue forecast at $12,785,842,944.
In 2028, BEAM is forecast to generate $14,023,837,261 in revenue, with the lowest revenue forecast at $1,206,029,709 and the highest revenue forecast at $27,363,733,399.